BRTX BioRestorative Therapies, Inc.

NASDAQ
$0.23

BioRestorative Therapies, Inc. (BRTX) is expected to report earnings on August 25, 2026, after the market close. The consensus earnings estimate is a loss of $0.15 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +24.8% since its last earnings release on May 14, 2026.

BioRestorative Therapies Beat Consensus Estimates
Thursday, May 14, 2026 · 12:00 AM ET
Earnings Date
2nd Quarter, Jun 2026
Aug 25
Tuesday · After Close
Earnings Whisper
-
vs ($0.15)
Rev est $70K
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $0.42

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. The company's core programs consist of Disc/Spine Program and Metabolic Program. Disc/Spine Program consists of cell therapy candidate, brtxDISC(TM) is a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow. Metabolic Program consists of ThermoStem(R), developing an allogeneic cell-based therapy to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. BioRestorative Therapies, Inc. is based in Melville, New York.

Sector

Healthcare

Industry

Biotechnology